Vascular Biogenics Ltd. [NASDAQ: VBLT] jumped around 0.01 points on Monday, while shares priced at $0.23 at the close of the session, up 5.45%. The company report on August 15, 2022 that VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor.
VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Vascular Biogenics Ltd. stock is now -88.22% down from its year-to-date (YTD) trading value. VBLT Stock saw the intraday high of $0.2418 and lowest of $0.2114 per share. The company’s 52-week high price is 2.54, which means current price is +15.71% above from all time high which was touched on 07/11/22.
Compared to the average trading volume of 3.39M shares, VBLT reached a trading volume of 4880703 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Vascular Biogenics Ltd. [VBLT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VBLT shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VBLT stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Vascular Biogenics Ltd. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on July 20, 2022. The new note on the price target was released on July 20, 2022, representing the official price target for Vascular Biogenics Ltd. stock. Previously, the target price had yet another raise to $5.50, while Oppenheimer analysts kept a Outperform rating on VBLT stock.
The Average True Range (ATR) for Vascular Biogenics Ltd. is set at 0.03, with the Price to Sales ratio for VBLT stock in the period of the last 12 months amounting to 23.65. The Price to Book ratio for the last quarter was 0.42, with the Price to Cash per share for the same quarter was set at 0.62.
How has VBLT stock performed recently?
Vascular Biogenics Ltd. [VBLT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.41. With this latest performance, VBLT shares gained by 5.45% in over the last four-week period, additionally sinking by -84.00% over the last 6 months – not to mention a drop of -88.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBLT stock in for the last two-week period is set at 27.78, with the RSI for the last a single of trading hit 31.59, and the three-weeks RSI is set at 29.19 for Vascular Biogenics Ltd. [VBLT]. The present Moving Average for the last 50 days of trading for this stock 0.8791, while it was recorded at 0.2208 for the last single week of trading, and 1.4646 for the last 200 days.
Vascular Biogenics Ltd. [VBLT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Vascular Biogenics Ltd. [VBLT] shares currently have an operating margin of -3905.73 and a Gross Margin at -111.07. Vascular Biogenics Ltd.’s Net Margin is presently recorded at -3895.83.
Return on Equity for this stock declined to -72.01, with Return on Assets sitting at -56.26.
Vascular Biogenics Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.20 and a Current Ratio set at 4.20.
Insider trade positions for Vascular Biogenics Ltd. [VBLT]
There are presently around $1 million, or 20.50% of VBLT stock, in the hands of institutional investors. The top three institutional holders of VBLT stocks are: LION POINT CAPITAL, LP with ownership of 2,593,286, which is approximately 0% of the company’s market cap and around 23.95% of the total institutional ownership; IKARIAN CAPITAL, LLC, holding 830,007 shares of the stock with an approximate value of $0.19 million in VBLT stocks shares; and MORGAN STANLEY, currently with $0.14 million in VBLT stock with ownership of nearly -2.534% of the company’s market capitalization.
Positions in Vascular Biogenics Ltd. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 14 institutional holders increased their position in Vascular Biogenics Ltd. [NASDAQ:VBLT] by around 635,263 shares. Additionally, 9 investors decreased positions by around 1,097,959 shares, while 10 investors held positions by with 4,202,223 shares. The mentioned changes placed institutional holdings at 5,935,445 shares, according to the latest SEC report filing. VBLT stock had 8 new institutional investments in for a total of 375,605 shares, while 3 institutional investors sold positions of 566,426 shares during the same period.